Video

Elizabeth Swisher Discusses Rucaparib's Side Effects for Patients With Ovarian Cancer

Author(s):

Elizabeth Swisher, M.D.
Conference|SGO Annual Meeting on Women's Cancer

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.

While overall deemed to be well-tolerated, the most common side effects that were experienced by patients were nausea, vomiting, fatigue, and anemia. These side effects get significantly better over the course of treatment.

Related Videos
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short black hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of man with black hair.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Image of a man wearing a black suit and tie.
Related Content
Image of doctor consulting man with prostate cancer.
October 22nd 2024

Treatment Side Effects, Quality of Life Factors in Prostate Cancer

Ashley Chan
It’s crucial for patients with prostate cancer to know that all treatments come with side effects, which may affect their quality of life.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of PSA test.
October 21st 2024

Rise in PSA Levels May Predict Treatment Response in Prostate Cancer

Spencer Feldman
The rate at which PSA rises after hormonal therapy for prostate cancer is a key factor in determining the effectiveness of the treatment.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of doctor consulting man.
October 16th 2024

Next-Generation Imaging a ‘Gold Standard’ in Metastatic Prostate Cancer

Ashley Chan
Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET imaging, an expert explained.
Image of researchers doing lab tests.
October 15th 2024

Why ‘Genetic Testing is Critical’ in Patients with Prostate Cancer

Alex Biese
As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in treatment decision-making for many.